Biora Therapeutics(BIOR) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Biora Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results Phase 1 clinical trial results for BT-600 demonstrate precise drug delivery to the colon with low systemic exposure, supporting clinical development plan Company secures up to $16M funding from existing investors supported by BT-600 results and progress toward BioJet TM partnership Management will host conference call and webcast today at 4:30 PM Eastern / 1:30 PM Pacific SAN DIEGO, August 12, 2024 – ...